Health-Related Quality of Life in Patients with Adult-Onset Myotonic Dystrophy Type 1: A Systematic Review by Landfeldt, E. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/207160
 
 
 
Please be advised that this information was generated on 2020-09-08 and may be subject to
change.
Vol.:(0123456789)
The Patient - Patient-Centered Outcomes Research (2019) 12:365–373 
https://doi.org/10.1007/s40271-019-00357-y
SYSTEMATIC REVIEW
Health‑Related Quality of Life in Patients with Adult‑Onset Myotonic 
Dystrophy Type 1: A Systematic Review
Erik Landfeldt1,2  · Josefin Edström3 · Cecilia Jimenez‑Moreno4 · Baziel G. M. van Engelen5 · Janbernd Kirschner6 · 
Hanns Lochmüller6,7,8
Published online: 4 February 2019 
© The Author(s) 2019
Abstract
Background Adult-onset myotonic dystrophy type 1 (DM1) is a chronic, multisystem disorder that leads to disability and 
premature death.
Objectives The objective of our study was to conduct a systematic literature review of the health-related quality of life 
(HRQoL) of patients with DM1.
Methods We searched Embase, Web of Science, and PubMed for English language full-text articles reporting results from 
studies of HRQoL in patients with adult-onset DM1 published between 1 January 2000 and 21 February 2018. We excluded 
reviews, editorials, and studies reporting results for a sample with fewer than five patients (to allow for meaningful inference).
Results The search identified 266 unique publications. Of these, 231 were excluded following title and abstract screening and 
16 after full-text review, leaving 19 articles for data synthesis. We found 15 articles measuring the HRQoL of patients with 
adult-onset DM1 using the 36-Item Short Form Health Survey (SF-36), six using the Individualized Neuromuscular Quality of 
Life Questionnaire (INQoL), and one using Cantril’s Ladder. Available evidence shows that patient HRQoL is impaired in DM1, 
mainly due to compromised physical health, but also reveals that substantial heterogeneity exists in estimates across studies.
Conclusions HRQoL in adult-onset DM1 has been extensively studied using the SF-36 and the INQoL, but current estimates 
are inconclusive, and little is known of the impact of the disease as measured using other instruments. Our data synthesis 
should help characterize the patient burden of DM1 and inform future studies of HRQoL in this indication.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 1-019-00357 -y) contains 
supplementary material, which is available to authorized users.
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Key Points for Decision Makers 
A range of studies has examined health-related quality of 
life (HRQoL) in myotonic dystrophy type 1 (DM1) using 
the 36-Item Short Form Health Survey and the Individu-
alized Neuromuscular Quality of Life Questionnaire, but 
exploration using other instruments is lacking (particu-
larly preference-based scales).
Our review of HRQoL in DM1 reveals substantial 
heterogeneity in published estimates of the latent trait 
across studies and samples.
Our synthesis contributes to the understanding of the 
health burden of the disease and should help to inform 
future research of HRQoL in DM1.
1 Introduction
Myotonic dystrophy type 1 (DM1) is a chronic, progres-
sive multisystem disorder of variable severity that leads 
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to disability and premature death [1]. It is inherited in 
an autosomal dominant manner and represents the most 
common muscular dystrophy in adults, with an estimated 
prevalence in Europe of between 10 and 18 per 100,000 
people [2]. For many patients, DM1 is associated with 
an array of different complications, including but not 
limited to muscle weakness, fatigue, cardiac conduction 
defects, excessive daytime sleepiness (EDS), endocrine 
disturbance, and gastrointestinal problems [1, 3]. It is also 
common for several members of the same family to be 
affected, resulting in a substantial health burden at the 
household level. Currently, only symptomatic treatments 
are available, but potentially more effective therapies are 
under investigation [3].
A number of recent studies have investigated the health-
related quality of life (HRQoL) of patients with disabling 
neuromuscular diseases, including DM1. The aim of our 
study was to review the literature about the HRQoL of 
patients with adult-onset DM1. Specifically, this systematic 
literature review sought to answer the following questions:
• In which geographical settings has the HRQoL of 
patients with adult-onset DM1 been studied?
• What instruments have been used to measure the HRQoL 
of patients with adult-onset DM1?
• What is known of the HRQoL of patients with adult-
onset DM1?
2  Methods
This systematic literature review was conducted and reported 
in accordance with the PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses) statement [4].
2.1  Search Strategy
We searched Embase, Web of Science, and PubMed for 
full-text articles reporting results from studies of HRQoL 
in DM1. The search string contained a combination of the 
following medical subject heading terms, title/abstract, and 
topic field tags: myotonic dystrophy, myotonic dystrophy 
type 1, DM1, Steinert’s disease, quality of life, health-
related quality of life, utility, and well-being (see the Elec-
tronic Supplementary Material [ESM] for the full search 
strings). We excluded (1) articles published before the 
year 2000 (to ensure estimates of HRQoL reflected current 
standard-of-care practices), (2) reviews and editorials, (3) 
articles in a language other than English, and (4) studies 
reporting results for a sample of fewer than five patients 
(to allow for meaningful inference). For studies including 
patients with different indications, we also required that 
results were reported separately for patients with adult-
onset DM1. Given our objective was to review studies of 
HRQoL, we did not include publications only reporting data 
concerning specific disease complications, manifestations, 
or domains of psychological or physical health, for exam-
ple, depression, pain, or fatigue, and we also excluded con-
genital myotonic dystrophy and childhood/juvenile-onset 
myotonic dystrophy (as the measurement of HRQoL in 
pediatric populations requires specific considerations [5]). 
Lastly, we excluded studies only reporting changes in meas-
ures of HRQoL or correlations between HRQoL and other 
outcomes/instruments.
2.2  Screening, Data Extraction, and Synthesis 
of Results
The search was performed on 21 February 2018. Two 
independent investigators (EL and JE) initially screened 
article titles and abstracts for eligibility and subsequently 
reviewed the full-text versions of selected records. The 
following data were extracted from all articles included 
in the review: author, year of publication, setting, sample, 
methods for measuring HRQoL (including employed instru-
ments), and main results. The reasons for article exclusion 
were recorded, and potential disagreements were resolved 
by consensus or, if necessary, with the involvement of a 
third investigator (HL). Results data from each article were 
synthesized and reported with respect to the three review 
questions listed in Sect. 1. Data presented in graphs were 
extracted using a specialized graph-digitizing software 
(DigitizeIt). We did not compare results from generic 
instruments with general population reference data (where 
available), as published normative estimates have been 
shown to vary across, for example, geographical settings 
and age groups and by sex [6]. We assessed study quality 
and risk of bias using the National Institute of Health Qual-
ity Assessment Tool for Observational Cohort and Cross-
Sectional Studies [7].
3  Results
The systematic literature review identified 469 publica-
tions (Fig. 1). Of these, 203 were duplicates, 231 records 
were excluded following title and abstract screening, and 
35 articles were selected for full-text review. Finally, 19 
articles [8–26] were considered for data synthesis. Table 1 
summarizes the data from the included publications and 
the outcomes from the study quality and bias assessments. 
Only one study [17] was judged to be of poor quality 
because of unclear reporting and validity of the outcome 
of interest.
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3.1  In Which Geographical Settings 
has the Health‑Related Quality of Life (HRQoL) 
of Patients with Adult‑Onset Myotonic 
Dystrophy Type 1 (DM1) been Studied?
We identified estimates of HRQoL for patients with adult-
onset DM1 from eight countries from three continents 
(Europe, North America, and South America) (Table 1). 
With the exception of Serbia, which accounted for 37% (7 
of 19) of all identified records, studies of samples from other 
countries were limited to one, two, or three publications.
3.2  What Instruments Have Been Used to Measure 
the HRQoL of Patients with Adult‑Onset DM1?
In total, 15 articles [8, 9, 11–14, 17–24, 26] used the 36-Item 
Short Form Health Survey (SF-36), six [9, 10, 15, 16, 23, 
25] used the Individualized Neuromuscular Quality of Life 
Questionnaire (INQoL), and one [24] used Cantril’s Ladder 
(CL) to measure the HRQoL of patients with adult-onset 
DM1.
3.3  What is Known of the HRQoL of Patients 
with Adult‑Onset DM1?
Figures 2 and 3 summarize the results from studies using the 
SF-36 instrument (comprising eight subscales, as well as two 
summary measures, each scored between 0 and 100, where 
a higher score represents greater HRQoL). Three studies [8, 
19, 26] found that patients had lower scores across all SF-36 
subscales than matched controls from the general population 
or general population reference data, whereas two [20, 24] 
reported lower physical health but not mental health (MH). 
Across studies and sample populations, mean scores were 
as follows: physical functioning (PF; 38–82), role physical 
(RP; 22–95), bodily pain (BP; 51–82), general health (GH; 
34–77), vitality (31–69), social functioning (SF; 56–93), role 
emotional (RE; 28–96), and MH (53–81). Mean physical 
component summary (PCS) and mental component sum-
mary (MCS) scores, respectively, were estimated at 38 and 
41 [13], 42 and 53 [20], 42 and 47 [12], 52 and 56 [14], 70 
and 76 [14], 37 and 48 [24], 42 and 45 (baseline visit) [11], 
and 50 and 59 (follow-up visit) [11]. In addition, one study 
published a mix of median and mean SF-36 scores. Specifi-
cally, Sansone et al. [9] estimated the median scores as PF 
60, RP 75, BP 82, SF 75, RE 100, MH 68, PCS 49, and 
MCS 51 and mean scores as GH 45 and vitality 51. Only one 
study [23] reported HRQoL in terms of utilities derived from 
the SF-36 (through the Short Form Six-Dimensions [SF-
6D] algorithm). The median utility was estimated at 0.710 
for employed patients and 0.678 for unemployed patients 
(utility estimates for other subgroups, or the pooled sample, 
were not reported). It should be noted that one study [17] 
appeared to report SF-36 scores incorrectly (the median 
“SF-36/quality of life” was estimated at >100).
Figure 4 presents the mean INQoL results, where a higher 
score represents a higher disease burden and lower HRQoL. 
Across studies and sample populations, mean scores ranged 
as follows: muscle weakness (49–70), muscle locking 
(38–63), pain (25–42), fatigue (42–60), activities (35–55), 
independence (30–47), social relationships (10–23), emo-
tions (24–44), and body image (6–62). In addition, one study 
published median INQoL scores. Specifically, Sansone et al. 
[9] estimated median scores across instrument domains as 
47, 32, 0, 42, 29, 17, 4, 19, and 25, respectively. Heatwole 
et al. [23] reported only total INQoL scores for patients who 
were employed (29) and unemployed (42).
Lastly, Geirdal et al. [24] estimated the mean score from 
CL (single-item scale ranging from 0 = worst possible qual-
ity of life to 10 = best possible quality of life) as 5.85. This 
estimate was not statistically different from the mean score 
of healthy relatives or next of kin without DM1.
4  Discussion
The aim of this study was to conduct a systematic litera-
ture review of studies investigating the HRQoL of patients 
with adult-onset DM1. Taken together, our results show that 
Records idenfied through database searching: n=469
- Embase: n=153
- PubMed: n=147
- Web of Science: n=169
Records aer duplicates removed: n=266
Full-text arcles assessed for 
eligibility: n=35
Arcles excluded: n=16
- No HRQoL esmates reported: n=8
- No results for adult onset DM1: n=8
Records screened: n=266 Records excluded: n=231
Studies included in qualitave synthesis: n=19
Fig. 1  PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) diagram of the selection process of the included 
publications. DM1 myotonic dystrophy type 1, HRQoL health-related 
quality of life
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Table 1  Summary data of included publications
Study, setting Sample Instrument (s) Main finding (s) Quality rating
Kalkman et al. [22], The Nether-
lands
N = 322: 151 M, 171 F; mean age 
43 y, range 18–63
SF-36 Age, severe fatigue associated with 
significantly lower scores across 
all SF-36 subscales
Good
Antonini et al. [26], Italy N = 20: 11 M, 9 F; median age 37 y, 
range 24–63
SF-36 Pts had, on average, lower scores 
across all SF-36 subscales vs. 
matched controls from general 
population
Good
Laberge et al. [21], Canada N = 200: 79 M, 121 F; mean age 47 
y, range 20–81
SF-36 Pts with fatigue had significantly 
lower scores across all SF-36 
subscales
Good
Orlikowski et al. [17], France N = 28: 15 M, 13 F; mean age 40 y, 
range 18–69
SF-36 SF-36 data incorrectly reported 
(median “SF-36/QOL” was >100)
Poor
Araújo et al. [19], Brazil N = 23: 13 M, 10 F; mean age 40 y, 
range NR
SF-36 Pts had, on average, lower scores 
across all SF-36 subscales vs. 
general population reference data
Fair
Peric et al. [13], Serbia N = 79: 41 M, 38 F; mean age 45 y, 
range NR
SF-36 Mean instrument scores not statisti-
cally different between DM1 and 
ALS, with the exception of the BP 
subscale
Good
Tieleman et al. [8], the Netherlands N = 29: 9 M, 20 F; mean age 53 y, 
range 28–72
SF-36 Pts had, on average, lower age- and 
sex-adjusted scores across all 
SF-36 subscales (except BP) vs. 
general population controls
Good
Sansone et al. [9], Italy N = 382: sex NR; mean age 46 y, 
range NR
INQoL, SF-36 HRQoL was impaired in pts with 
DM1, perceived as detrimental, 
and similar to estimates for skel-
etal muscle channelopathies
Fair
Laberge et al. [20], Canada N = 200: 79 M, 121 F; mean age 47 
y, range NR
SF-36 Pts scored lower on all SF-36 physi-
cal health subscales vs. normative 
data but did not differ with respect 
to mental health
Good
Peric et al. [12], Serbia N = 120: 70 M, 50 F; mean age 46 
y, range NR
SF-36 Pts had impaired HRQoL as 
assessed through physical and 
mental instrument subscales
Good
Peric et al. [14], Serbia N = 25: all M; mean age 44 y, range 
22–58
SF-36 Erectile dysfunction was associated 
with a significantly lower mean 
MCS score
Good
Rakocevic-Stojanovic et al. [10], 
Serbia
N = 44: 19 M, 25 F; mean age 46 y, 
range NR
INQoL Several disease manifestations had 
a clear impact on pt HRQoL. 
Severity of fatigue was the most 
important predictor of total 
INQoL score
Good
Geirdal et al. [24], Norway N = 13: 6 M, 7 F; mean age 41 y, 
range 18–61
CL, SF-36 Pts with DM1 had significantly 
lower PF, GH, VT, and PCS 
scores than healthy relatives or 
next of kin without DM1 but 
similar mental health and compa-
rable overall HRQoL as assessed 
through CL
Fair
Peric et al. [16], Serbia N = 52: 23 M, 29 F; mean age 45 y, 
range NR
INQoL Majority of pts with DM1 had mild 
to moderate pain
Good
Baldanzi et al. [25], Italy N = 65: 41 M, 24 F; mean age 46 y, 
range 18–70
INQoL Pts reported mild overall impact 
of disease disability on HRQoL. 
Weakness and fatigue instrument 
domains were associated with the 
largest, and body image and social 
relationships with the smallest, 
impact on HRQoL
Good
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HRQoL in this patient population is well-explored using the 
SF-36 and the INQoL in several settings, but estimates from 
other rating scales are lacking, particularly preference-based 
instruments (i.e., instruments linked to utilities).
As shown in Figs.  2 and 3, our synthesis of patient 
HRQoL as measured through the SF-36 revealed a trend of 
impairment (in relation to the maximum score of 100) across 
all instrument subscales, particularly RP, GH, and vitality, 
yet estimates varied substantially between studies. This het-
erogeneity may be related to differences in patient samples 
(e.g., disease severity and prevalence of complications, as 
well as demographical and cultural factors) [6] but may also 
be a function of the psychometric properties of the scale. For 
instance, the SF-36 is an ordinal scale and would thus not be 
expected to fulfil the strict criteria of fundamental measure-
ment, which is a requirement for invariant comparison [27, 
28]. Indeed, although it is clear that a lower/higher score 
indicates lower/higher HRQoL, how a specific score, or dif-
ferences in scores at various points across the continuum, 
should be interpreted is unknown. The notable variability in 
point estimates from the SF-36 identified in this review also 
indicates that the rating scale may not achieve invariance, 
which means it is affected by the sample it is measuring (i.e., 
not “stable”) [28]. This means that the estimated continuum, 
and the location of items on the continuum, is not sample 
independent and that the scale fails to “transcend the group 
measured” [29]. For these reasons, it may not be meaningful 
to directly compare mean estimates across study samples, or 
even between patients, or with general population reference 
data. Accordingly, the validity of the SF-36 as a measure of 
HRQoL in patients with adult-onset DM1 warrants further 
investigation, preferably using modern psychometric meth-
ods, such as Rasch analysis [30]. Thus, in agreement with 
Peric et al. [11], we suggest that estimates from the SF-36 in 
this indication should be interpreted with caution.
Similar to outcomes from the SF-36, our synthesis of 
results from the INQoL indicated impairment in patient 
HRQoL across many instrument domains, particularly mus-
cle weakness, muscle locking, and fatigue, but also revealed 
non-trivial differences between assessments (Fig. 4). Given 
its scoring structure, the INQoL would be expected to be 
subject to similar psychometric issues as noted for the 
SF-36. That being said, the instrument records a relatively 
rich set of information on a range of aspects that would be 
expected to be associated with HRQoL—including self-per-
ceived disease burden; amount and perceived importance of 
symptoms; ability to perform daily, work, and leisure activi-
ties; and impact on relationships—so we think it may still, 
depending on study design, be of interest and relevance to 
include the tool in future research involving patients with 
DM1.
The lack of psychometric data for scales used to meas-
ure latent traits, such as health status, HRQoL, and ability 
to perform activities of daily living, in patients with DM1 
was also noted in a recently published literature review of 
patient-reported outcome measures in this indication [31]. 
In particular, the authors found that the validity of many 
instruments has not been thoroughly investigated and that 
disease-specific properties, such as responsiveness and mini-
mal clinically important difference thresholds, are needed 
for all measures (although it should be noted that the SF-36 
was not included in the review). Further research into these 
topics is strongly encouraged to ensure the tools employed 
are fit for purpose [32].
We only identified two point estimates of patient HRQoL 
in terms of utilities. This was a bit surprising given that 
Table 1  (continued)
Study, setting Sample Instrument (s) Main finding (s) Quality rating
Peric et al. [11], Serbia N = 62: 33 M, 29 F; mean age 43 y, 
range NR
SF-36 Pt HRQoL improved across study 
follow-up (5 y)
Good
Peric et al. [15], Serbia N = 67: 35 M, 32 F; mean age 42 y, 
range NR
INQoL Pt HRQoL improved across study 
follow-up (6 y)
Good
O’Donoghue et al. [18], France N = 12: 5 M, 7 F; mean age 50 y, 
range NR
SF-36 Pts derived little benefit in terms 
of HRQoL from noninvasive 
ventilation
Fair
Heatwole et al. [23], USA N = 52: 20 M, 32 F; mean age 43 y, 
range 18–69
INQoL, SF-36 Median SF-6D utility was estimated 
at 0.710 for employed pts and 
0.678 for unemployed pts
Good
Point estimates from the INQoL and SF-36 are reported in Figs. 1, 2, and 3 or in the text. Quality and risk of bias were assessed using the 
National Institute of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [7]
ALS amyotrophic lateral sclerosis, BP bodily pain, CL Cantril’s Ladder, DM1 myotonic dystrophy type 1, F female, GH general health, HrQoL 
health-related quality of life, INQoL Individualized Neuromuscular Quality of Life Questionnaire, M male, MCS mental component summary, 
NR not reported, PCS mean physical component summary, PF physical functioning, pt(s) patient(s), QOL quality of life, SF-36 36-Item Short 
Form Health Survey, SF-6D Short Form Six-Dimension, VT vitality, y year(s)
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outcomes from the SF-36 can be mapped to utilities (through 
the SF-6D). In general, utility estimates derived from mem-
bers of the general population would be expected to provide 
additional, complementary information about the patient 
burden of a disease, as they reflect preferences for health 
states (as dictated by the disease, among other factors) from 
the perspective of healthy individuals ex ante experienc-
ing the health state. In fact, there are several reasons why 
patients and members of the general population would attrib-
ute a different preference weight to a specific health state 
(e.g., being affected by DM1). First, individuals from the 
general population may be subject to a process known as 
“focalism” or “focusing illusion” [33, 34], where positive 
aspects of a health state are underestimated or neglected 
because the attention is focused on negative consequences. 
Second, patients may learn to cope with their illness and/
or disability, adjust their perception and expectations of 
HRQoL, and adapt to their health state, a phenomenon 
known as “response shift” or “well-being paradox” [5]. 
Evidence of such coping mechanisms has been noted in 
previous research in patients with DM1 [11, 15] or other 
genetic, chronic illnesses, such as Duchenne muscular dys-
trophy [35] or cerebral palsy [36]. Third, patients and the 
general population may have different vantage points, with 
patients assessing their health state in terms of the benefits 
that would result from regaining health, whereas members 
of the general population may view the health state in terms 
of the costs associated with losing good health [37]. As a 
consequence, among patients, changes in health states gov-
erning HRQoL may not be fully detected using rating scales 
such as the SF-36 and INQoL. On the other hand, estimates 
of HRQoL measured in terms of utilities will vary across 
health states as classified by the instruments. Yet, it is not 
certain that instruments linked to utilities map out health 
states (using the included items and levels) that are rele-
vant to DM1, or the efficacy of interventions in the context 
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Fig. 2  Health-related quality of life of patients with adult-onset myo-
tonic dystrophy type 1 as measured using the. A higher score repre-
sents greater health-related quality of life. For references, see Table 1. 
We only included baseline results from the study by O’Donoghue 
et al. [18] because there were no significant differences across follow-
up. Subgroups from Laberge et al. [21]: [A] fatigue, [B] fatigue and 
excessive daytime sleepiness, [C] excessive daytime sleepiness, and 
[D] neither fatigue nor excessive daytime sleepiness. Subgroups from 
Peric et al. [11]: [E] baseline and [F] after 5 years
371HRQoL in Patients with Myotonic Dystrophy Type 1
of clinical trials, and may therefore lack sensitivity. This 
would be expected to be the case in DM1 with, for exam-
ple, a very short, generic instrument such as the EuroQol 
Five-Dimensions (EQ-5D). Moreover, bearing in mind that 
appraisals of pricing and reimbursement of orphan drugs in 
most countries also include evidence of cost effectiveness 
[38], estimates of HRQoL in terms of utilities will also be 
important to facilitate economic evaluations of future health 
technologies targeting DM1.
Although of uncertain relevance given the psychometric 
limitations of the SF-36 and INQoL as noted, several studies 
have explored how these tools correlate with other measures 
in patients with DM1. Total and subscale scores from the 
SF-36 have been shown to be inversely correlated with, for 
example, age [11–13, 22–26]; duration and/or severity of 
disease [11–13, 20, 21, 26]; fatigue [12, 20, 22]; depression, 
anxiety, psychological distress, and/or neuroticism [11–13, 
20, 21, 24, 26]; intellectual quotient [20]; and EDS [20] and 
positively correlated with education [11–13]. Moreover, the 
INQoL has been shown to be positively correlated with, for 
example, age [10], measures of disease severity [10, 23], 
depression and anxiety [10], and pain [16] and inversely 
correlated with education [10]. However, it is worth noting 
that these findings are not exhaustive, and studies may have 
reached alternative conclusions with regards to the correla-
tions between SF-36 and INQoL total and subscale scores, 
respectively, and other variables.
The main clinical implication of this review, in addition 
to informing the design of and selection of endpoints for 
future patient trials of new interventions (as discussed), con-
cerns the identified variability in estimates within the current 
body of evidence, indicative of the heterogeneous presenta-
tion of DM1. Indeed, evident from our data synthesis, DM1 
appears to have a highly variable but nontrivial impact (in 
relation to maximum scale scores) across many domains of 
patients’ lives, underscoring the need for a patient-centered 
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Fig. 3  Health-related quality of life of patients with adult-onset myo-
tonic dystrophy type 1 as measured using the 36-Item Short Form 
Health Survey (SF-36). A higher score represents greater health-
related quality of life. For references, see Table 1. We only included 
baseline results from the study by O’Donoghue et  al. [18] because 
there were no significant differences across follow-up. No estimate 
for vitality was published by Kalkman et  al. [22]. Subgroups from 
Laberge et  al. [21]: [A] fatigue, [B] fatigue and excessive daytime 
sleepiness, [C] excessive daytime sleepiness, and [D] neither fatigue 
nor excessive daytime sleepiness. Subgroups from Peric et  al. [11]: 
[E] baseline and [F] after 5 years
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and holistic approach to disease management. For this rea-
son, it may also be of interest to further explore the burden 
of DM1 on informal caregivers (e.g., partners, family mem-
bers, and close friends), who often play an integral part in 
the provision of long-term care in many illness [39].
5  Conclusion
HRQoL in adult-onset DM1 has been extensively studied 
using the SF-36 and the INQoL, but current estimates are 
inconclusive and little is known of the impact of the disease 
as measured using other instruments. Our data synthesis 
should help characterize the patient burden of DM1 and 
inform future studies of HRQoL in this indication.
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